New hope for advanced breast cancer: umbrella trial tests smart drug combos

NCT ID NCT05933395

Recruiting now Disease control Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study is testing several drug combinations (fulvestrant plus either neratinib, alpelisib, or everolimus) in 135 postmenopausal women with advanced ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitor treatment. The goal is to see which combination offers the best chance of stabilizing or shrinking tumors. Participants are assigned to a treatment arm based on their tumor's genetic profile.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fulvestrant, neratinib, alpelisib, everolimus
What this could lead to: If successful, this could identify effective drug combinations for patients whose cancer has stopped responding to standard CDK4/6 inhibitors, potentially slowing disease progression.
What could go wrong: This is a mid-stage trial with only 135 participants, so results may not apply to all patients. Side effects from the drug combinations could be significant, and not all arms may show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer hormone receptor-positive breast cancer Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED BREAST CANCER

Contacts and locations

Locations

Dartmouth Hitchcock Medical Center
RECRUITING

Lebanon, New Hampshire, 03756, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.